Impact of Pre-Exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination | Zendy

Lisa C. Lindesmith | Zendy; Michael L. Mallory | Zendy; Taylor Jones | Zendy; Charles C. Richardson | Zendy; Robert R. Goodwin | Zendy; Frank Baehner | Zendy; Paul M. Mendelman | Zendy; Robert F. Bargatze | Zendy; Ralph S. Baric | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Impact of Pre-Exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination

Author(s) -

Lisa C. Lindesmith,

Michael L. Mallory,

Taylor Jones,

Charles C. Richardson,

Robert R. Goodwin,

Frank Baehner,

Paul M. Mendelman,

Robert F. Bargatze,

Ralph S. Baric

Publication year - 2017

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jix045

Subject(s) - avidity , norovirus , virology , vaccination , antibody , biology , immunology , medicine , virus

Development of high avidity, broadly neutralizing antibodies (Abs) is a priority after vaccination against rapidly evolving, widely disseminated viruses like human norovirus. After vaccination with a multivalent GI.1 and GII.4c norovirus virus-like particle (VLP) vaccine candidate adjuvanted with alum and monophosphoryl lipid A (MPL), blockade Ab titers peaked early, with no increase in titer following a second vaccine dose.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research